Obesity diminishes response to PD-1-based immunotherapies in renal cancer

Abstract

We find that obesity is associated with diminished efficacy of anti-PD-1-based therapies in renal cancer, due in part to increased inflammatory IL-1β levels, highlighting the need for continued study of this critical issue.